Statins Linked to Lower Dementia Risk in Type 2 Diabetes Patients, Danish

A new Danish observational study has found that starting statin therapy after a diagnosis of type 2 diabetes may be associated with a reduced risk of dementia. The research draws attention because individuals with type 2 diabetes face a higher baseline risk of dementia, and no effective treatment for dementia currently exists.

Study design and participant cohort

Researchers used data from Denmark’s national health registry. The analysis included 132,585 individuals diagnosed with type 2 diabetes between 2006 and 2019 who had not used statins prior to their diabetes diagnosis. Participants were grouped according to the timing of their first statin prescription relative to diagnosis: within one year, or between one and five years later. Their dementia incidence was then compared with that of individuals who never received statins.

Dementia risk reduction by timing of statin initiation

Among those who began statin treatment within 12 months of diagnosis, dementia risk was 15% lower after 10 years of follow-up compared with non-users. For those who started statins one to five years after diagnosis, the corresponding risk reduction was 10% over the same period.

In absolute terms, the 10-year dementia incidence was 3.9% among statin non-users, 3.5% among those who initiated therapy later (one to five years post-diagnosis), and 3.3% among those who began treatment within the first year after diagnosis.

Why statins? The cholesterol–diabetes–dementia nexus

Statins are prescribed primarily to lower low-density lipoprotein cholesterol (LDL-C), a modifiable cardiovascular risk factor. People with type 2 diabetes frequently experience dyslipidaemia, and elevated LDL-C is identified as a modifiable dementia risk factor in the 2024 Lancet Commission on dementia prevention.

This overlap—between type 2 diabetes, high LDL-C, and dementia risk—prompted investigators to examine whether statin use might correlate with lower dementia incidence in this population.

Dr. Thomas Ternehammer of Copenhagen University Hospital, who led the study, stated: “In individuals diagnosed with type 2 diabetes, statin use was associated with a lower risk of dementia, and this association was more pronounced among those who initiated treatment early.”

Causality remains unproven

The researchers emphasize that the observational nature of the study precludes conclusions about causation. It identifies an association—not proof that statins directly prevent dementia.

Professor Isabel Gonçalves, a cardiovascular researcher at the European Society of Cardiology who was not involved in the study, noted that people with type 2 diabetes already carry an elevated dementia risk and are routinely advised to lower cholesterol to reduce heart attack and stroke risk. She added that the findings suggest early statin initiation after diagnosis may be linked to a modest reduction in dementia risk—and that earlier initiation may offer greater benefit than delayed treatment.

The precise biological mechanism underlying the observed association remains unknown, and the authors state that further research is needed to clarify potential pathways.

Nonetheless, the team considers the results noteworthy, particularly given that statins are already widely prescribed to manage cardiovascular risk in many patients with type 2 diabetes.